


=>
Uploading C:\Program Files\Stnexp\Queries\10693794elected.str



chain nodes :
8 9 18 19 20 21 22 23 24 25 26 27 28 29 30
ring nodes :
1 2 3 4 5 6 7 10 11 12 13 14 15 16 17
chain bonds :
1-9 2-7 2-30 3-26 3-27 4-28 4-29 5-8 6-19 10-21 10-22 13-20 14-18 15-23
16-24 17-25
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 7-10 7-13 10-11 11-12 11-14 12-13 12-17 14-15
15-16 16-17
exact/norm bonds :
1-2 1-6 1-9 2-3 2-7 3-4 4-5 5-6 5-8 7-10 7-13 10-11 12-13 13-20 14-18

exact bonds :
2-30 3-26 3-27 4-28 4-29 6-19 10-21 10-22 15-23 16-24 17-25
normalized bonds :
11-12 11-14 12-17 14-15 15-16 16-17

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:CLASS 9:CLASS 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:CLASS 19:CLASS
20:CLASS 21:CLASS
22:CLASS 23:CLASS 24:CLASS 25:CLASS 26:CLASS 27:CLASS 28:CLASS 29:CLASS
30:CLASS

L1 STRUCTURE UPLOADED

=> s 11
SAMPLE SEARCH INITIATED 14:12:14 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 93 TO ITERATE

100.0% PROCESSED 93 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
 BATCH **COMPLETE**
PROJECTED ITERATIONS: 1282 TO 2438
PROJECTED ANSWERS: 0 TO 0

L2 0 SEA SSS SAM L1

=> s 11 fam full
FULL SEARCH INITIATED 14:12:21 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 269 TO ITERATE

100.0% PROCESSED 269 ITERATIONS
SEARCH TIME: 00.00.01


7 ANSWERS

L3 7 SEA FAM FUL L1

=> d 13 scan

L3 7 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 2,6-Piperidinedione, 3-(4-amino-1,3-dihydro-1-oxo-2H-isoindol-2-yl)-,
(3S)-
MF C13 H13 N3 O3

Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):2

L3 7 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 2,6-Piperidinedione, 3-(4-amino-1,3-dihydro-1-oxo-2H-isoindol-2-yl)-,
(3R)-
MF C13 H13 N3 O3


Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 7 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 2,6-Piperidinedione, 3-(4-amino-1,3-dihydro-1-oxo-2H-isoindol-2-yl)-


MF C13 H13 N3 O3
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):4


L3 7 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 2,6-Piperidinedione, 3-(4-amino-1,3-dihydro-1-oxo-2H-isoindol-2-yl)-,
dihydrate (9CI)
MF C13 H13 N3 O3 . 2 H2 O



●2 H2O


L3 7 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 2,6-Piperidinedione, 3-(4-amino-1,3-dihydro-1-oxo-2H-isoindol-2-yl)-, (-)-
MF C13 H13 N3 O3

Rotation (-).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L3 7 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 2,6-Piperidinedione, 3-(4-amino-1,3-dihydro-1-oxo-2H-isoindol-2-yl)-,
hydrate (2:1)
MF C13 H13 N3 O3 . 1/2 H2 O



● 1/2 H2O

L3 7 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 2,6-Piperidinedione, 3-(4-amino-1,3-dihydro-1-oxo-2H-isoindol-2-yl)-, (+)-
MF C13 H13 N3 O3

Rotation (+).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

ALL ANSWERS HAVE BEEN SCANNED

=> file caplus		SINCE FILE	TOTAL
COST IN U.S. DOLLARS		ENTRY	SESSION
FULL ESTIMATED COST		70.57	70.78

FILE 'CAPLUS' ENTERED AT 14:12:52 ON 29 FEB 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is

held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 29 Feb 2008 VOL 148 ISS 10
FILE LAST UPDATED: 28 Feb 2008 (20080228/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s 13/thu
360 L3
984144 THU/RL
L4 345 L3/THU
(L3 (L) THU/RL)

=> file stnguide
COST IN U.S. DOLLARS SINCE FILE TOTAL
ENTRY SESSION
FULL ESTIMATED COST 2.60 73.38

FILE 'STNGUIDE' ENTERED AT 14:13:00 ON 29 FEB 2008
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Feb 22, 2008 (20080222/UP).

=> file hcplus
COST IN U.S. DOLLARS SINCE FILE TOTAL
ENTRY SESSION
FULL ESTIMATED COST 0.12 73.50

FILE 'HCPLUS' ENTERED AT 14:14:07 ON 29 FEB 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 29 Feb 2008 VOL 148 ISS 10
FILE LAST UPDATED: 28 Feb 2008 (20080228/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s (complex regional pain syndrome) or (reflex sympathetic dystrophy) or fibromyalgia

1393825 COMPLEX
71559 REGIONAL
57456 PAIN
138750 SYNDROME
138 COMPLEX REGIONAL PAIN SYNDROME
(COMPLEX(W)REGIONAL(W)PAIN(W)SYNDROME)
26070 REFLEX
40962 SYMPATHETIC
13868 DYSTROPHY
202 REFLEX SYMPATHETIC DYSTROPHY
(REFLEX(W)SYMPATHETIC(W)DYSTROPHY)
1304 FIBROMYALGIA
L5 1506 (COMPLEX REGIONAL PAIN SYNDROME) OR (REFLEX SYMPATHETIC DYSTROPHY) OR FIBROMYALGIA

=> s 14 and 15

COMMAND INTERRUPTED

If this message appears repeatedly, please notify the Help Desk.
Enter "HELP STN" for information on contacting the nearest STN Help Desk by telephone or via SEND in the STNMAIL file.

=> s 16 and (PY<2003 or AY<2003 or PRY<2003)

L6 NOT FOUND

The L-number entered could not be found. To see the definition of L-numbers, enter DISPLAY HISTORY at an arrow prompt (=>).

=> file stnguide

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	2.69	76.19

FILE 'STNGUIDE' ENTERED AT 14:14:10 ON 29 FEB 2008
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Feb 22, 2008 (20080222/UP).

=> file hcplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.06	76.25

FILE 'HCPLUS' ENTERED AT 14:14:31 ON 29 FEB 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December

26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 29 Feb 2008 VOL 148 ISS 10
FILE LAST UPDATED: 28 Feb 2008 (20080228/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s 14 and 15

COMMAND INTERRUPTED

If this message appears repeatedly, please notify the Help Desk. Enter "HELP STN" for information on contacting the nearest STN Help Desk by telephone or via SEND in the STNMAIL file.

=> fiel caplus

FIEL IS NOT A RECOGNIZED COMMAND

The previous command name entered was not recognized by the system. For a list of commands available to you in the current file, enter "HELP COMMANDS" at an arrow prompt (=>).

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

FULL ESTIMATED COST

ENTRY

TOTAL

2.69

SESSION

78.94

FILE 'CAPLUS' ENTERED AT 14:14:40 ON 29 FEB 2008

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 29 Feb 2008 VOL 148 ISS 10
FILE LAST UPDATED: 28 Feb 2008 (20080228/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s 14 and 15

1393825 COMPLEX

71559 REGIONAL

57456 PAIN

138750 SYNDROME

```
138 COMPLEX REGIONAL PAIN SYNDROME
  (COMPLEX(W)REGIONAL(W)PAIN(W)SYNDROME)
26070 REFLEX
40962 SYMPATHETIC
13868 DYSTROPHY
  202 REFLEX SYMPATHETIC DYSTROPHY
  (REFLEX(W)SYMPATHETIC(W)DYSTROPHY)
1304 FIBROMYALGIA
  4 L4 AND L5
L6
```

```
=> d 16 1-4 ti bas bib
'BAS' IS NOT A VALID FORMAT FOR FILE 'CAPLUS'
```

The following are valid formats:

```
ABS ----- GI and AB
ALL ----- BIB, AB, IND, RE
APPS ----- AI, PRAI
BIB ----- AN, plus Bibliographic Data and PI table (default)
CAN ----- List of CA abstract numbers without answer numbers
CBIB ----- AN, plus Compressed Bibliographic Data
CLASS ----- IPC, NCL, ECLA, FTERM
DALL ----- ALL, delimited (end of each field identified)
DMAX ----- MAX, delimited for post-processing
FAM ----- AN, PI and PRAI in table, plus Patent Family data
FBIB ----- AN, BIB, plus Patent FAM
IND ----- Indexing data
IPC ----- International Patent Classifications
MAX ----- ALL, plus Patent FAM, RE
PATS ----- PI, SO
SAM ----- CC, SX, TI, ST, IT
SCAN ----- CC, SX, TI, ST, IT (random display, no answer numbers;
  SCAN must be entered on the same line as the DISPLAY,
  e.g., D SCAN or DISPLAY SCAN)
STD ----- BIB, CLASS

IABS ----- ABS, indented with text labels
IALL ----- ALL, indented with text labels
IBIB ----- BIB, indented with text labels
IMAX ----- MAX, indented with text labels
ISTD ----- STD, indented with text labels

OBIB ----- AN, plus Bibliographic Data (original)
OIBIB ----- OBIB, indented with text labels

SBIB ----- BIB, no citations
SIBIB ----- IBIB, no citations

HIT ----- Fields containing hit terms
HITIND ----- IC, ICA, ICI, NCL, CC and index field (ST and IT)
  containing hit terms
HITRN ----- HIT RN and its text modification
HITSTR ----- HIT RN, its text modification, its CA index name, and
  its structure diagram
HITSEQ ----- HIT RN, its text modification, its CA index name, its
  structure diagram, plus NTE and SEQ fields
FHITSTR ----- First HIT RN, its text modification, its CA index name, and
  its structure diagram
PHITSEQ ----- First HIT RN, its text modification, its CA index name, its
  structure diagram, plus NTE and SEQ fields
KWIC ----- Hit term plus 20 words on either side
```

OCC ----- Number of occurrence of hit term and field in which it occurs

To display a particular field or fields, enter the display field codes. For a list of the display field codes, enter HELP DFIELDS at an arrow prompt (>). Examples of formats include: TI; TI,AU; BIB,ST; TI,IND; TI,SO. You may specify the format fields in any order and the information will be displayed in the same order as the format specification.

All of the formats (except for SAM, SCAN, HIT, HITIND, HITRN, HITSTR, FHITSTR, HITSEQ, FHITSEQ, KWIC, and OCC) may be used with DISPLAY ACC to view a specified Accession Number.

ENTER DISPLAY FORMAT (BIB):ti abs bib

L6 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2008 ACS on STN
TI Methods and compositions using immunomodulators for the treatment, prevention or management of dysfunctional sleep and dysfunctional sleep associated with disease
AB Methods are disclosed for treating, preventing and/or managing dysfunctional sleep, including but not limited to, dysfunctional sleep associated with chronic neurol. or inflammatory condition such as pain and neurodegenerative disorders, which comprise the administration of one or more immunomodulatory compds. or a pharmaceutically acceptable salt, solvate, stereoisomer, clathrate or prodrug thereof, alone or in combination with known therapeutics. Pharmaceutical compns., single unit dosage forms, and kits suitable for use in methods of the invention are also disclosed. Immunomodulatory compds. include e.g.
4-amino-2-[2,6-dioxo(3-piperidyl)]isoindoline-1,3-dione.

AN 2005:1078258 CAPLUS <>LOGINID::20080229>>

DN 143:339698

TI Methods and compositions using immunomodulators for the treatment, prevention or management of dysfunctional sleep and dysfunctional sleep associated with disease

IN Zeldis, Jerome B.; Manning, Donald C.; Faleck, Herbert

PA USA

SO U.S. Pat. Appl. Publ., 21 pp.

CODEN: USXXCO

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 2005222209	A1	20051006	US 2005-93848	20050330
AU 2005231415	A1	20051020	AU 2005-231415	20050331
CA 2561910	A1	20051020	CA 2005-2561910	20050331
WO 2005097125	A2	20051020	WO 2005-US10937	20050331
WO 2005097125	A3	20070125		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG				
EP 1740178	A2	20070110	EP 2005-731426	20050331
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA,				

HR, LV, MK, YU				
CN 1980667	A	20070613	CN 2005-80017546	20050331
BR 2005009400	A	20070828	BR 2005-9400	20050331
JP 2007531770	T	20071108	JP 2007-506569	20050331
MX 2006PA11216	A	20070116	MX 2006-PA11216	20060929
KR 2007007880	A	20070116	KR 2006-722827	20061031
PRAI US 2004-559261P	P	20040401		
WO 2005-US10937	W	20050331		
L6 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2008 ACS on STN				
TI Methods of using and compositions comprising immunomodulatory compounds for treatment, modification, and management of pain				
AB Methods for treating, preventing, modifying and managing various types of pain are disclosed. Specific methods comprise the administration of an immunomodulatory compound, or a pharmaceutically acceptable salt, solvate, hydrate, stereoisomer, clathrate, or prodrug thereof, alone or in combination with a second active agent and/or surgery, psychol. or phys. therapy. Pharmaceutical compns., single unit dosage forms, and kits suitable for use in methods of the invention are also disclosed.				
AN 2005:426405 CAPLUS <>LOGINID:20080229>				
DN 142:457122				
TI Methods of using and compositions comprising immunomodulatory compounds for treatment, modification, and management of pain				
IN Zeldis, Jerome B.; Faleck, Herbert; Manning, Donald C.				
PA Celgene Corporation, USA				
SO PCT Int. Appl., 62 pp.				
CODEN: PIXXD2				
DT Patent				
LA English				
FAN.CNT 6				
PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	-----	-----	-----	-----
PI WO 2005044178	A2	20050519	WO 2004-US12721	20040423
WO 2005044178	A3	20051027		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TG, TG				
US 2005203142	A1	20050915	US 2003-693794	20031023
AU 2004286818	A1	20050519	AU 2004-286818	20040423
CA 2543160	A1	20050519	CA 2004-2543160	20040423
EP 1680111	A2	20060719	EP 2004-750612	20040423
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
BR 2004015007	A	20061107	BR 2004-15007	20040423
CN 1897945	A	20070117	CN 2004-80038171	20040423
JP 2007525484	T	20070906	JP 2006-536542	20040423
MX 2006PA04427	A	20060627	MX 2006-PA4427	20060421
IN 2006CN01805	A	20070608	IN 2006-CN1805	20060523
US 2007244078	A1	20071018	US 2007-576152	20070213
PRAI US 2003-693794	A	20031023		
US 2002-421003P	P	20021024		
WO 2004-US12721	W	20040423		
OS MARPAT 142:457122				

L6 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2008 ACS on STN
 TI Vaccines for cancer, autoimmune disease and infections
 AB The author discloses tumor-associated HLA-restricted peptides for treating or preventing cancers in a patient. In specific aspects, the peptides are derived from neutrophil elastase, cyclin E1, cyclin D, or cyclin E2. Such peptides can be used to elicit specific CTLs that preferentially attack tumor cells (e.g., myeloid leukemia). The present invention also provides HLA-restricted antigens as vaccines for treating or preventing autoimmune diseases or conditions, transplant rejection or vasculitis. In particular aspects, there is provided PR3, a myeloid tissue-restricted protein and a HLA-A2.1-restricted self-peptide, PR1, derived from PR3, which can be used to elicit PR1-specific CTLs.

AN 2005:347136 CAPLUS <>LOGINID:20080229>>

DN 142:409698

TI Vaccines for cancer, autoimmune disease and infections

IN Mollrem, Jeffrey

PA Board of Regents, the University of Texas System, USA

SO PCT Int. Appl., 235 pp.

CODEN: PIXXD2

DT Patent

LA English


FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005035714	A2	20050421	WO 2004-US27792	20040826
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	EP 1670899	A2	20060621	EP 2004-809624	20040826
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
PRAI US	2003-498238P	P	20030826		
	WO 2004-US27792	W	20040826		

L6 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2008 ACS on STN

TI Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain

GI



AB Methods of treating, preventing, modifying and managing various types of pain are disclosed. Specific methods comprise the administration of an

immunomodulatory compound of formula (I), or a pharmaceutically acceptable salt, solvate, hydrate, stereoisomer, clathrate, or prodrug thereof, alone or in combination with a second active agent and/or surgery, psychol. or phys. therapy. Pharmaceutical compns., single unit dosage forms, and kits suitable for use in methods of the invention are also disclosed.

AN 2004:368888 CAPLUS <>LOGINID:20080229>>

DN 140:368712

TI Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain

IN Zeldis, Jerome B.; Faleck, Herbert; Manning, Donald C.

PA Celgene Corporation, USA

SO PCT Int. Appl., 53 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 6

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004037199	A2	20040506	WO 2003-US33757	20031024
	WO 2004037199	A3	20041223		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2503536	A1	20040506	CA 2003-2503536	20031024
	AU 2003286663	A1	20040513	AU 2003-286663	20031024
	EP 1556044	A2	20050727	EP 2003-777871	20031024
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	BR 2003015609	A	20050823	BR 2003-15609	20031024
	CN 1732000	A	20060208	CN 2003-80107531	20031024
	JP 2006507284	T	20060302	JP 2004-547126	20031024
	CN 101108185	A	20080123	CN 2007-10103924	20031024
	MX 2005PA04182	A	20050608	MX 2005-PA4182	20050420
PRAI	US 2002-421003P	P	20021024		
	CA 2003-80107531	A3	20031024		
	WO 2003-US33757	W	20031024		
OS	MARPAT	140:368712			

=> d his

(FILE 'HOME' ENTERED AT 14:11:36 ON 29 FEB 2008)

FILE 'REGISTRY' ENTERED AT 14:11:47 ON 29 FEB 2008

L1 STRUCTURE UPLOADED

L2 0 S L1

L3 7 S L1 FAM FULL

FILE 'CAPLUS' ENTERED AT 14:12:52 ON 29 FEB 2008

L4 345 S L3/THU

FILE 'STNGUIDE' ENTERED AT 14:13:00 ON 29 FEB 2008

FILE 'HCAPLUS' ENTERED AT 14:14:07 ON 29 FEB 2008

L5 1506 S (COMPLEX REGIONAL PAIN SYNDROME) OR (REFLEX SYMPATHETIC DYSTR
FILE 'STNGUIDE' ENTERED AT 14:14:10 ON 29 FEB 2008
FILE 'HCAPLUS' ENTERED AT 14:14:31 ON 29 FEB 2008
FILE 'CAPLUS' ENTERED AT 14:14:40 ON 29 FEB 2008
L6 4 S L4 AND L5

=> log hold
COST IN U.S. DOLLARS SINCE FILE TOTAL
ENTRY SESSION
FULL ESTIMATED COST 29.08 108.02
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) SINCE FILE TOTAL
ENTRY SESSION
CA SUBSCRIBER PRICE -3.20 -3.20

SESSION WILL BE HELD FOR 120 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 14:14:57 ON 29 FEB 2008

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAEX01623

PASSWORD:
* * * * * RECONNECTED TO STN INTERNATIONAL * * * * *
SESSION RESUMED IN FILE 'CAPLUS' AT 14:17:11 ON 29 FEB 2008
FILE 'CAPLUS' ENTERED AT 14:17:11 ON 29 FEB 2008
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

COST IN U.S. DOLLARS SINCE FILE TOTAL
ENTRY SESSION
FULL ESTIMATED COST 29.08 108.02
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) SINCE FILE TOTAL
ENTRY SESSION
CA SUBSCRIBER PRICE -3.20 -3.20

=> file hcaplus
COST IN U.S. DOLLARS SINCE FILE TOTAL
ENTRY SESSION
FULL ESTIMATED COST 30.04 108.98
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) SINCE FILE TOTAL
ENTRY SESSION
CA SUBSCRIBER PRICE -3.20 -3.20

FILE 'HCAPLUS' ENTERED AT 14:18:16 ON 29 FEB 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available

for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 29 Feb 2008 VOL 148 ISS 10
FILE LAST UPDATED: 28 Feb 2008 (20080228/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s pain or (TNF-alpha) or (tumor necrosis factor)

57456 PAIN
74498 TNF
1747308 ALPHA
56524 TNF-ALPHA
(TNF(W)ALPHA)
442058 TUMOR
136569 NECROSIS
1104219 FACTOR
73524 TUMOR NECROSIS FACTOR
(TUMOR(W)NECROSIS(W)FACTOR)
L7 149488 PAIN OR (TNF-ALPHA) OR (TUMOR NECROSIS FACTOR)

=> s 14 and 17

COMMAND INTERRUPTED

If this message appears repeatedly, please notify the Help Desk.
Enter "HELP STN" for information on contacting the nearest STN Help Desk by telephone or via SEND in the STNMAIL file.

=> s 18 and (PY<2003 or AY<2003 or PRY<2003)

L8 NOT FOUND

The L-number entered could not be found. To see the definition of L-numbers, enter DISPLAY HISTORY at an arrow prompt (>).

=> file stnguide

	SINCE FILE	TOTAL
	ENTRY	SESSION
COST IN U.S. DOLLARS		
FULL ESTIMATED COST	2.69	111.67
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	0.00	-3.20

FILE 'STNGUIDE' ENTERED AT 14:18:19 ON 29 FEB 2008
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Feb 22, 2008 (20080222/UP).

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.06	111.73
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-3.20

FILE 'CAPLUS' ENTERED AT 14:18:38 ON 29 FEB 2008
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 29 Feb 2008 VOL 148 ISS 10
 FILE LAST UPDATED: 28 Feb 2008 (20080228/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

```
=> s 14 and 17
      57456 PAIN
      74498 TNF
      1747308 ALPHA
      56524 TNF-ALPHA
          (TNF(W)ALPHA)
      442058 TUMOR
      136569 NECROSIS
      1104219 FACTOR
      73524 TUMOR NECROSIS FACTOR
          (TUMOR(W)NECROSIS(W)FACTOR)
```

L8 53 L4 AND L7

```
=> s 18 and (PY<2003 or PRY<2003 or AY<2003)
      22929004 PY<2003
      3953937 PRY<2003
      4478702 AY<2003
```

L9 18 L8 AND (PY<2003 OR PRY<2003 OR AY<2003)

=> d 19 1-18 ti abs bib

```
L9  ANSWER 1 OF 18  CAPLUS  COPYRIGHT 2008 ACS on STN
TI  Methods of using and compositions comprising immunomodulatory compounds
    for treatment, modification, and management of pain
AB  Methods for treating, preventing, modifying and managing various types of
    pain are disclosed. Specific methods comprise the administration
    of an immunomodulatory compound, or a pharmaceutically acceptable salt,
    solvate, hydrate, stereoisomer, clathrate, or prodrug thereof, alone or in
    combination with a second active agent and/or surgery, psychol. or phys.
```

therapy. Pharmaceutical compns., single unit dosage forms, and kits suitable for use in methods of the invention are also disclosed.

AN 2005:426405 CAPLUS <>LOGINID::20080229>>

DN 142:457122

TI Methods of using and compositions comprising immunomodulatory compounds for treatment, modification, and management of pain

IN Zeldis, Jerome B.; Faleck, Herbert; Manning, Donald C.

PA Celgene Corporation, USA

SO PCT Int. Appl., 62 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 6

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005044178	A2	20050519	WO 2004-US12721	20040423
	WO 2005044178	A3	20051027		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US	2005203142	A1	20050915	US 2003-693794	20031023 <--
AU	2004286818	A1	20050519	AU 2004-286818	20040423
CA	2543160	A1	20050519	CA 2004-2543160	20040423
EP	1680111	A2	20060719	EP 2004-750612	20040423
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
BR	2004015007	A	20061107	BR 2004-15007	20040423
CN	1897945	A	20070117	CN 2004-80038171	20040423
JP	2007525484	T	20070906	JP 2006-536542	20040423
MX	2006PA04427	A	20060627	MX 2006-PA4427	20060421
IN	2006CN01805	A	20070608	IN 2006-CN1805	20060523
US	2007244078	A1	20071018	US 2007-576152	20070213
PRAI	US 2003-693794	A	20031023		
	US 2002-421003P	P	20021024	<--	
	WO 2004-US12721	W	20040423		
OS	MARPAT	142:457122			

L9 ANSWER 2 OF 18 CAPLUS COPYRIGHT 2008 ACS on STN

TI Methods and compositions using immunomodulatory compounds for treatment and management of cancers and other angiogenesis-associated diseases

AB Methods are disclosed for treating, preventing and/or managing cancer, as well as and diseases and disorders associated with, or characterized by, undesired angiogenesis. Specific methods encompass the administration of an immunomodulatory compound alone or in combination with a second active ingredient. The invention further discloses methods for reducing or avoiding adverse side effects associated with chemotherapy, radiation therapy, hormonal therapy, biol. therapy or immunotherapy, which comprise the administration of an immunomodulatory compound. Pharmaceutical compns., single unit dosage forms, and kits suitable for use in methods of the invention are also disclosed.

AN 2004:1033549 CAPLUS <>LOGINID::20080229>>

DN 142:758

TI Methods and compositions using immunomodulatory compounds for treatment

and management of cancers and other angiogenesis-associated diseases
IN Zeldis, Jerome B.
PA Celgene Corporation, USA
SO PCT Int. Appl., 73 pp.
CODEN: PIXXD2

DT Patent
LA English
FAN.CNT 6

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004103274	A2	20041202	WO 2004-US14004	20040505
	WO 2004103274	A3	20050303		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2004029832	A1	20040212	US 2003-438213	20030515 <--
	CA 2505128	A1	20040527	CA 2003-2505128	20031106 <--
	AU 2003290651	A1	20040603	AU 2003-290651	20031106 <--
	AU 2003290651	B2	20080131		
	EP 1567158	A2	20050831	EP 2003-783233	20031106 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	BR 2003016050	A	20050913	BR 2003-16050	20031106 <--
	JP 2006514689	T	20060511	JP 2005-507108	20031106 <--
	US 2006199843	A1	20060907	US 2003-704237	20031106 <--
	US 7323479	B2	20080129		
	AU 2004240548	A1	20041202	AU 2004-240548	20040505
	CA 2525557	A1	20041202	CA 2004-2525557	20040505
	EP 1635826	A2	20060322	EP 2004-751400	20040505
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
	BR 2004010306	A	20060523	BR 2004-10306	20040505
	CN 1822834	A	20060823	CN 2004-80020445	20040505
	JP 2006528973	T	20061228	JP 2006-532787	20040505
	MX 2005PA04734	A	20050802	MX 2005-PA4734	20050503 <--
	MX 2005PA12155	A	20060222	MX 2005-PA12155	20051111
	IN 2005CN03418	A	20070727	IN 2005-CN3418	20051215
	AU 2006202316	A1	20060622	AU 2006-202316	20060531
PRAI	US 2003-438213	A	20030515		
	US 2003-704237	A	20031106		
	US 2002-380842P	P	20020517 <--		
	US 2002-424600P	P	20021106 <--		
	AU 2003-234626	A3	20030516		
	WO 2003-US35544	W	20031106		
	WO 2004-US14004	W	20040505		
OS	MARPAT 142:758				

L9 ANSWER 3 OF 18 CAPLUS COPYRIGHT 2008 ACS on STN
TI Methods of using and compositions comprising immunomodulatory compounds
for the treatment and management of myeloproliferative diseases
AB Methods of treating, preventing and/or managing a myeloproliferative
disease are disclosed. Specific methods encompass the administration of
an immunomodulatory compound, or a pharmaceutically acceptable salt,

solvate, hydrate, stereoisomer, clathrate, or prodrug thereof, alone or in combination with a second active agent, and/or the transplantation of blood or cells. Particular second active agents are capable of suppressing the overprodn. of hematopoietic stem cells or ameliorating one or more of the symptoms of myeloproliferative disease. Pharmaceutical compns., single unit dosage forms, and kits suitable for use in methods of the invention are also disclosed. The immunomodulatory compound is especially 4-(amino)-2-[2,6-dioxo(3-piperidyl)]isoindoline-1,3-dione or 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)piperidine-2,6-dione.

AN 2004:372856 CAPLUS <LOGINID:20080229>

DN 140:368680

TI Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of myeloproliferative diseases

IN Zeldis, Jerome B.

PA USA

SO U.S. Pat. Appl. Publ., 20 pp.

CODEN: USXXCO

DT Patent

LA English


FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004087546	A1	20040506	US 2003-411656	20030411 <--
	CA 2504663	A1	20040527	CA 2003-2504663	20030413 <--
	WO 2004043464	A1	20040527	WO 2003-US11328	20030413 <--
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KE, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2003241289	A1	20040603	AU 2003-241289	20030413 <--
	AU 2003241289	B2	20080103		
EP	1567157	A1	20050831	EP 2003-731018	20030413 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	BR 2003016082	A	20050927	BR 2003-16082	20030413 <--
	CN 1720045	A	20060111	CN 2003-825761	20030413 <--
	JP 2006507325	T	20060302	JP 2004-551395	20030413 <--
	ZA 2005003666	A	20060830	ZA 2005-3666	20030413 <--
	MX 2005PA04778	A	20051005	MX 2005-PA4778	20050504 <--
	US 2006166932	A1	20060727	US 2006-371777	20060308 <--
PRAI	US 2002-424730P	P	20021106	<--	
	US 2003-411656	A3	20030411		
	WO 2003-US11328	W	20030413		
OS	MARPAT	140:368680			

L9 ANSWER 4 OF 18 CAPLUS COPYRIGHT 2008 ACS on STN

TI Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain

GI



AB Methods of treating, preventing, modifying and managing various types of pain are disclosed. Specific methods comprise the administration of an immunomodulatory compound of formula (I), or a pharmaceutically acceptable salt, solvate, hydrate, stereoisomer, clathrate, or prodrug thereof, alone or in combination with a second active agent and/or surgery, psychol. or phys. therapy. Pharmaceutical compns., single unit dosage forms, and kits suitable for use in methods of the invention are also disclosed.

AN 2004:368888 CAPLUS <<LOGINID::20080229>>

DN 140:368712

II Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain.

PA Celgene Corporation, USA

SO PCT Int. Appl., 53 pp.

CODEN: P1XXD2

DT Rate

DI Facette
LA English

ENGLISH
FAN-CNT 6

FANONI &
PATEN

FAIRE

BT WO 2004037

	WO 2004037199	A2	20040306	WO 2003-0533757	20031024
	WO 2004037199	A3	20041223		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KE, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BE, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2503536		A1	20040506	CA 2003-2503536	20031024 <--
AU 2003286663		A1	20040513	AU 2003-286663	20031024 <--
EP 1556044		A2	20050727	EP 2003-777871	20031024 <--
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003015609		A	20050823	BR 2003-15609	20031024 <--
CN 1732000		A	20060208	CN 2003-80107531	20031024 <--
JP 2006507284		T	20060302	JP 2004-547126	20031024 <--
CN 101108185		A	20080123	CN 2007-10103924	20031024 <--
MX 2005PA04182		A	20050608	MX 2005-PA4182	20050420 <--
PRAI US 2002-421003P		P	20021024	<--	
CN 2003-80107531		A3	20031024		
WO 2003-US33757		W	20031024		

16 ANSWER E OF 18 CARLIS. COPYRIGHT 2009 AGS - STML

L9 ANSWER 5 OF 18 CAPLUS COPYRIGHT 2008 ACS on STN
TI Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of myelodysplastic syndromes

AB Methods of treating, preventing and/or managing myelodysplastic syndromes are disclosed. Specific methods encompass the administration of immunomodulatory compound, or a pharmaceutically acceptable salt, solvate, hydrate, stereoisomer, clathrate, or prodrug thereof, alone or in combination with a second active ingredient, and/or the transplantation of blood or cells. Specific second active ingredients are capable of affecting or improving blood cell production. Pharmaceutical compns., single unit dosage forms, and kits suitable for use in methods of the invention are also disclosed. Patients with myelodysplastic syndromes were treated orally with 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione.

AN 2004:354803 CAPLUS <<LOGINID:20080229>>

DN 140:350572

TI Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of myelodysplastic syndromes

IN Zeldis, Jerome B.

PA Celgene Corporation, USA

SO PCT Int. Appl., 47 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004035064	A1	20040429	WO 2003-US11323	20030413 <--
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KE, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2004220144	A1	20041104	US 2003-411649	20030411 <--
	US 7189740	B2	20070313		
	CA 2477301	A1	20040429	CA 2003-2477301	20030413 <--
	AU 2003228508	A1	20040504	AU 2003-228508	20030413 <--
	EP 1487461	A1	20041222	EP 2003-726262	20030413 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	BR 2003015315	A	20050816	BR 2003-15315	20030413 <--
	CN 1713917	A	20051228	CN 2003-825567	20030413 <--
	JP 20060507271	T	20060302	JP 2004-545192	20030413 <--
	MX 2005PA03888	A	20050622	MX 2005-PA3888	20050412 <--
	ZA 2005003025	A	20060628	ZA 2005-3025	20050414 <--
	JP 2007045839	A	20070222	JP 2006-278102	20061011 <--
	US 2007196330	A1	20070823	US 2007-654550	20070116 <--
	KR 2007020141	A	20070216	KR 2007-701593	20070123 <--
PRAI	US 2002-418468P	P	20021015	<--	
	US 2003-411649	A3	20030411		
	JP 2004-545192	A3	20030413		
	WO 2003-US11323	W	20030413		
	KR 2005-706539	A3	20050415		

OS MARPAT 140:350572

RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 6 OF 18 CAPLUS COPYRIGHT 2008 ACS on STN

TI Method using dialkyl ethers and other compounds for treating arthritis,

cartilage damage, and other interleukin 6-mediated conditions
AB The invention discloses combinations, compns., and methods using or having a substituted dialkyl ether, substituted aryl-alkyl ether, substituted dialkyl thioether, substituted dialkyl ketone, or substituted alkyl compound, or a pharmaceutically acceptable salt thereof, as an active component for preventing or treating osteoarthritis, preventing or inhibiting cartilage damage, preventing or treating rheumatoid arthritis, improving joint function, alleviating pain, including joint pain, and the like in a patient in need thereof. Compds. of the invention include e.g. 6-(5-carboxy-5-methyl-hexyloxy)-2,2-dimethylhexanoic acid calcium salt (CI-1027).

AN 2004:182691 CAPLUS <LOGINID:20080229s>

DN 140:210765

TI Method using dialkyl ethers and other compounds for treating arthritis, cartilage damage, and other interleukin 6-mediated conditions

IN Cornicelli, Joseph Anthony; Kilgore, Kenneth Stanley; Sliskovic, Drago Robert; Bove, Susan Elizabeth; Neideffer, David Herbert; Kowala, Mark Charles

PA Warner-Lambert Company LLC, USA

SO PCT Int. Appl., 117 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004017952	A1	20040304	WO 2003-IB3664	20030813 <--
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KE, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BE, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2004048910	A1	20040311	US 2003-639719	20030812 <--
	CA 2494544	A1	20040304	CA 2003-2494544	20030813 <--
	AU 2003255937	A1	20040311	AU 2003-255937	20030813 <--
	EP 1539127	A1	20050615	EP 2003-792585	20030813 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	BR 2003013883	A	20050719	BR 2003-13883	20030813 <--
	CN 1678297	A	20051005	CN 2003-819951	20030813 <--
	JP 2006501238	T	20060112	JP 2004-530464	20030813 <--
	MX 2005PA01254	A	20050608	MX 2005-PA1254	20050131 <--
	US 2007203212	A1	20070830	US 2007-738679	20070423 <--
PRAI	US 2002-405250P	P	20020822	<--	
	US 2003-475443P	P	20030603		
	US 2003-477092P	P	20030609		
	US 2003-484808P	P	20030703		
	US 2003-639719	A1	20030812		
	WO 2003-IB3664	W	20030813		

OS MARPAT 140:210765

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 7 OF 18 CAPLUS COPYRIGHT 2008 ACS on STN

TI Modulation of stem and progenitor cell differentiation, assays, and uses in transplantation and other medical treatments

AB The invention provides methods for modulating mammalian stem cell and progenitor cell differentiation. The methods can be employed to regulate and control the differentiation and maturation of mammalian, particularly human, stem cells along specific cell and tissue lineages. The methods of the invention relate to the use of certain small organic mols. (e.g. thalidomide analogs and isoindolone derivs.) to modulate the differentiation of stem or progenitor cell populations along specific cell and tissue lineages, and in particular, to the differentiation of embryonic-like stem cells originating from a postpartum placenta or for the differentiation of early progenitor cells to a granulocytic lineage. Finally, the invention discloses the use of such differentiated stem or progenitor cells in transplantation and other medical treatments.

AN 2003:837304 CAPLUS <>LOGINID:20080229>>

DN 139:317475

TI Modulation of stem and progenitor cell differentiation, assays, and uses in transplantation and other medical treatments

IN Hariri, Robert J.; Stirling, David I.; Chan, Kyle W. H.; Moutouh-de Parseval, Laure A.

PA Celgene Corporation, USA

SO PCT Int. Appl., 122 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003087392	A2	20031023	WO 2003-US11327	20030413 <--
	WO 2003087392	A9	20041229		
	WO 2003087392	A3	20050428		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US	2003235909	A1	20031225	US 2003-411655	20030411 <--
CA	2481386	A1	20031023	CA 2003-2481386	20030413 <--
AU	2003224945	A1	20031027	AU 2003-224945	20030413 <--
EP	1551953	A2	20050713	EP 2003-721642	20030413 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IS, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP	2006500911	T	20060112	JP 2003-584330	20030413 <--
CN	1756836	A	20060405	CN 2003-813627	20030413 <--
MX	2004PA0998	A	20041213	MX 2004-PA0998	20041012 <--
PRAI	US 2002-372348P	P	20020412	<--	
	US 2002-437348P	P	20021231	<--	
	US 2002-437350P	P	20021231	<--	
	WO 2003-US11327	W	20030413		

L9 ANSWER 8 OF 18 CAPLUS COPYRIGHT 2008 ACS on STN

TI Methods for identification of modulators of angiogenesis, compounds discovered thereby, and methods of treatment using the compounds

AB The invention provides methods for identifying modulators of angiogenesis using human cells. The methods of the invention can be employed to assay compds. for their ability to modulate human angiogenesis utilizing human pluripotent stem cells in an in vitro assay system. The invention further provides methods for identifying modulators of human angiogenesis by determining

the ability of a test compound to modulate spontaneous vasogenesis in an in vitro assay system utilizing nonembryonic pluripotent stem cells. The invention provides an in vitro assay systems using nonembryonic pluripotent stem cells for the identification of compds. that modulate human angiogenesis or human vasogenesis. The invention further provides methods of treatment which require modulation of human angiogenesis or vasogenesis, comprising administering to patients in need of such treatment compds. which have been identified to be inhibitors of human angiogenesis or vasogenesis.

AN 2003:836830 CAPLUS <>LOGINID::20080229>

DN 139:317453

TI Methods for identification of modulators of angiogenesis, compounds discovered thereby, and methods of treatment using the compounds

IN Hariri, Robert J.; Payvandi, Faribourz; Wu, Lei; Stirling, David I.; Ye, Qian

PA Celgene Corporation, USA

SO PCT Int. Appl., 81 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003086373	A1	20031023	WO 2003-US11578	20030414 <--
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KE, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2481387	A1	20031023	CA 2003-2481387	20030414 <--
	AU 2003237078	A1	20031027	AU 2003-237078	20030414 <--
	AU 2003237078	B2	20071108		
	EP 1496878	A1	20050119	EP 2003-736463	20030414 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	CN 1658848	A	20050824	CN 2003-813733	20030414 <--
	JP 2005536189	T	20051202	JP 2003-583394	20030414 <--
	NZ 536050	A	20071130	NZ 2003-536050	20030414 <--
	MX 2004PA09996	A	20050701	MX 2004-PA9996	20041012 <--
	US 2005148034	A1	20050707	US 2004-511354	20041222 <--
PRAI	US 2002-372127P	P	20020412 <--		
	WO 2003-US11578	W	20030414		

RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 9 OF 18 CAPLUS COPYRIGHT 2008 ACS on STN

TI Combination therapy including a JNK kinase inhibitor for treating, preventing or managing proliferative disorders and cancers

AB The invention provides methods and compns. designed for the treatment, management or prevention of cancer. The methods of the invention comprise the administration of an effective amount of one or more inhibitors of JNK in combination with the administration of an effective amount of one or more other agents useful for cancer therapy. The invention also provides pharmaceutical compns. comprising one or more inhibitors of JNK in combination with one or more other agents useful for cancer therapy. In particular, the invention provides methods of treatment and prevention of

cancer by the administration of an effective amount of one or more inhibitors of JNK in combination with standard and exptl. chemotherapies, hormonal therapies, bone marrow transplants, stem cell replacement therapies, biol. therapies/immunotherapies and/or radiation therapies for treatment or prevention of cancer. Also included are methods of treatment of cancer by the administration of one or more inhibitors of JNK in combination with surgery, alone or in further combination with standard and exptl. chemotherapies, hormonal therapies, bone marrow transplants, stem cell replacement therapies, biol. therapies/immunotherapies and/or radiation therapies. JNK inhibitors include e.g. indazole derivs.

AN 2003:737576 CAPLUS <>LOGINID:20080229>

DN 139:240349

TI Combination therapy including a JNK kinase inhibitor for treating, preventing or managing proliferative disorders and cancers

IN Stein, Bernd M.; Westwick, John K.; Ennis, Bruce W.

PA Signal Pharmaceuticals, Inc., USA

SO PCT Int. Appl., 109 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003075917	A1	20030918	WO 2003-US6894	20030307 <--
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KE, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2478338	A1	20030918	CA 2003-2478338	20030307 <--
	AU 2003217961	A1	20030922	AU 2003-217961	20030307 <--
	US 2004067953	A1	20040408	US 2003-384440	20030307 <--
	EP 1487436	A1	20041222	EP 2003-713937	20030307 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	JP 2005533748	T	20051110	JP 2003-574192	20030307 <--
	NZ 535349	A	20070126	NZ 2003-535349	20030307 <--
	ZA 2004007150	A	20051004	ZA 2004-7150	20040907 <--
	US 2007149571	A1	20070628	US 2007-704665	20070209 <--
PRAI	US 2002-362705P	P	20020308	<--	
	US 2003-384440	A	20030307		
	WO 2003-US6894	W	20030307		

OS MARPAT 139:240349

RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 10 OF 18 CAPLUS COPYRIGHT 2008 ACS on STN

TI Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma

AB Thalidomide (Thal) can overcome drug resistance in multiple myeloma (MM) but is associated with somnolence, constipation, and neuropathy. In previous *in vitro* studies, we have shown that the potent immunomodulatory derivative of thalidomide (IMiD) CC-5013 induces apoptosis or growth arrest even in resistant MM cell lines and patient cells, decreases binding of MM cells to bone marrow stromal cells (BMSCs), inhibits the production in the BM milieu of cytokines (interleukin-6 [IL-6], vascular endothelial growth factor

[VEGF], tumor necrosis factor- α [$TNF-\alpha$]) mediating growth and survival of MM cells, blocks angiogenesis, and stimulates host anti-MM natural killer (NK) cell immunity. Moreover, CC-5013 also inhibits tumor growth, decreases angiogenesis, and prolongs host survival in a human plasmacytoma mouse model. In the present study, we carried out a phase 1 CC-5013 dose-escalation (5 mg/d, 10 mg/d, 25 mg/d, and 50 mg/d) study in 27 patients (median age 57 yr; range, 40-71 yr) with relapsed and refractory relapsed MM. They received a median of 3 prior regimens (range, 2-6 regimens), including autologous stem cell transplantation and Thal in 15 and 16 patients, resp. In 24 evaluable patients, no dose-limiting toxicity (DLT) was observed in patients treated at any dose level within the first 28 days; however, grade 3 myelosuppression developed after day 28 in all 13 patients treated with 50 mg/d CC-5013. In 12 patients, dose reduction to 25 mg/d was well tolerated and therefore considered the maximal tolerated dose (MTD). Importantly, no significant somnolence, constipation, or neuropathy has been seen in any cohort. Best responses of at least 25% reduction in paraprotein occurred in 17 (71%) of 24 patients (90% confidence interval [CI], 52%-85%), including 11 (46%) patients who had received prior Thal. Stable disease (less than 25% reduction in paraprotein) was observed in an addnl. 2 (8%) patients. Therefore, 17 (71%) of 24 patients (90% CI, 52%-85%) demonstrated benefit from treatment. Our study therefore provides the basis for the evaluation of CC-5013, either alone or in combination, to treat patients with MM at earlier stages of disease.

AN 2002:840111 CAPLUS <<LOGINID::20080229>>

DN 138:83060

TI Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma

AU Richardson, Paul G.; Schlossman, Robert L.; Weller, Edie; Hidemitsu, Teru; Mitsiades, Constantine; Davies, Faith; LeBlanc, Richard; Catley, Laurence P.; Doss, Deborah; Kelly, Kathleen; McKenney, Mary; Mechlowicz, Julie; Freeman, Andrea; Deocampo, Reggie; Rich, Rebecca; Ryoo, Joan J.; Chauhan, Dharminder; Balinski, Kathe; Zeldis, Jerome; Anderson, Kenneth C.

CS Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA

SO Blood (2002), 100(9), 3063-3067

CODEN: BLOOAW; ISSN: 0006-4971

PB American Society of Hematology

DT Journal

LA English

RE.CNT 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 11 OF 18 CAPLUS COPYRIGHT 2008 ACS ON STN

TI Treatment of low back pain and whiplash-associated disorder with, for example, a monoclonal antibody, an antisense oligonucleotide, or an MMP inhibitor

AB The use of a substance that inhibits disk-related nerve-irritating substances for the production of a pharmaceutical composition for treatment of low

back pain and/or whiplash-associated disorder (WAD) is disclosed.

The substance that inhibits disk-related nerve-irritating substances is, e.g., a monoclonal antibody, a soluble cytokine receptor or a receptor antagonist, an antisense oligonucleotide, an MMP inhibitor, a quinolone, a thalidomide derivative, an inhibitor of IL-1, IL-6, IL-8, or IFN- γ , and a nitric oxide or eicosanoid blocking substance. Also a method for treatment of low back pain and/or whiplash-associated disorder (WAD) is disclosed. For example, a male patient diagnosed with sciatica due to disk herniation and whiplash-associated disorder (pain in the region of the neck that radiated out into both arms after a vehicle

accident) was treated with an i.v. injection of 2.5 mL of Orthogen (an IL-1 receptor antagonist) dissolved in 2.5 mL saline. The day after the injection, the patient reported that the sciatic pain was markedly reduced. His problems in the neck region were also greatly improved and minor stiffness in the neck and the radiating pain in the arms had more or less disappeared. At the follow-up examination 1 wk later, he reported that he only suffered minor pain in the legs and also in the neck. Four weeks after the injection, the patient considered himself free of symptoms, and this was the case also at the final follow-up examination at 8 wk.

AN 2002:793397 CAPLUS <LOGINID:20080229>

DN 137:289029

TI Treatment of low back pain and whiplash-associated disorder with, for example, a monoclonal antibody, an antisense oligonucleotide, or an MMP inhibitor

IN Olmarker, Kjell; Rydevik, Bjoern

PA A+ Science Invest AB, Swed.

SO PCT Int. Appl., 35 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 200208093	A1	20021017	WO 2002-SE673	20020405 <--
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KE, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2002249742	A1	20021021	AU 2002-249742	20020405 <--
PRAI	SE 2001-1258	A	20010406		<--
	WO 2002-SE673	W	20020405		<--

RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 12 OF 18 CAPLUS COPYRIGHT 2008 ACS on STN

TI Use of TNF inhibitor for treatment of whiplash associated disorder

AB The use of a tumor necrosis factor (TNF) inhibitor for the production of a pharmaceutical composition for treatment of whiplash associated disorder (WAD) is disclosed. Also a method for treatment of whiplash associated disorder (WAD) is disclosed. The inhibitor can be a specific TNF blocking substance (antibody, receptor antagonist, antisense oligonucleotide) or a non-specific TNF blocking substance (MMP inhibitor, quinolone, thalidomide, etc.).

AN 2002:793396 CAPLUS <LOGINID:20080229>

DN 137:289028

TI Use of TNF inhibitor for treatment of whiplash associated disorder

IN Olmarker, Kjell; Rydevik, Bjoern

PA A+ Science Invest AB, Swed.

SO PCT Int. Appl., 23 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

PI WO 2002080892 A1 20021017 WO 2002-SE672 20020405 <--
 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
 CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
 GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
 LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
 PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
 UA, UG, US, UZ, VN, YU, ZA, ZM, ZW
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
 CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
 BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
 AU 2002251630 A1 20021021 AU 2002-251630 20020405 <--
 PRAI SE 2001-1257 A 20010406 <--
 WO 2002-SE672 W 20020405 <--
 RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 13 OF 18 CAPLUS COPYRIGHT 2008 ACS on STN
 TI Use of a TNF inhibitor for the treatment of low back pain
 AB The use of a tumor necrosis factor (TNF)
 inhibitor for the production of a pharmaceutical composition for treatment of
 low

back pain and in particular of low back pain due to
 local irritation of annulus-related nerve fibers by disk derived
 substances is described. Also a method for treatment of low back
 pain is disclosed. For example, a patient was given infliximab, a
 selective monoclonal antibody that inhibits only TNF, at 5 mg/kg for
 treatment of low back pain. Approx. 1.5 h after completing the
 administration the patient started to feel symptoms of relief regarding
 his pain. The improvement was found to be dramatic at the
 follow-up exams. and persisted during 4 wk.

AN 2002:793395 CAPLUS <>LOGINID:20080229>>

DN 137:304790

TI Use of a TNF inhibitor for the treatment of low back pain

IN Olmarker, Kjell; Rydevik, Bjoern

PA A+ Science Invest AB, Swed.

SO PCT Int. Appl., 29 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2002080891	A1	20021017	WO 2002-SE671	20020405 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002249741	A1	20021021	AU 2002-249741	20020405 <--
PRAI SE 2001-1256	A	20010406	<--	
WO 2002-SE671	W	20020405	<--	
RE.CNT 8	THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD			
	ALL CITATIONS AVAILABLE IN THE RE FORMAT			

L9 ANSWER 14 OF 18 CAPLUS COPYRIGHT 2008 ACS on STN

TI Formulations of adenosine A1 agonists

AB A method of treating conditions associated with pain and

alleviating the symptoms associated with it comprises administering to a mammal an adenosine A1 agonist or a salt or solvate and an NSAID, e.g., a COX-2 inhibitor. The present invention also provides pharmaceutical formulations and patient packs comprising the combinations. Thus, (25,35,4R,5R)-2-(5-tert-butyl-[1,3,4]oxadiazol-2-yl)-5-[6-(4-chloro-2-fluorophenylamino)purin-9-yl]tetrahydrofuran-3,4-diol (I) was prepared in a series of steps by the reaction of (3aS,4S,6R,6aR)-6-(6-chloropurin-9-yl)-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxole-4-carboxylic acid with 2,2-dimethylpropionic acid hydrazide followed by the cyclization of the resulting compound, and subsequent treatment with 4-chloro-2-fluoroaniline and deprotection. I and 2-(4-ethoxy-phenyl)-3-(4-methanesulfonylphenyl)pyrazolo[1,5-b]pyridazine(COX-2 inhibitor), were administered at 1% to rats. The compds. showed inhibition of carrageenan-induced edema and allodynia.

AN 2001:472471 CAPLUS <<LOGINID::20080229>>

DN 135:81971

TI Formulations of adenosine A1 agonists

IN Bountra, Charanjit; Clayton, Nicholas Maughan; Naylor, Alan

PA Glaxo Group Limited, UK

SO PCT Int. Appl., 33 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001045683	A2	20010628	WO 2000-GB4883	20001219 <--
	WO 2001045683	A3	20020314		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP	1239879	A2	20020918	EP 2000-985627	20001219 <--
EP	1239879	B1	20040225		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP	2003519104	T	20030617	JP 2001-546422	20001219 <--
AT	260119	T	20040315	AT 2000-985627	20001219 <--
US	2003004128	A1	20030102	US 2002-168195	20020618 <--
PRAI	GB 1999-30075	A	19991220	<--	
	WO 2000-GB4883	W	20001219	<--	

L9 ANSWER 15 OF 18 CAPLUS COPYRIGHT 2008 ACS on STN

TI Compositions for the prevention and treatment of atherosclerosis and restenosis

AB Methods and compns. for the prevention and treatment of all forms of atherosclerosis are described. Administration of compds. such as thalidomide, its analogs, hydrolysis products, metabolites, derivs. and precursors as well as addnl. compds. capable of inhibiting tumor necrosis factor- α (TNF- α) are used in the invention. Also disclosed is the coating of prosthetic devices, such as stents, with the compds. of the invention for the prevention and/or treatment of restenosis. Tablets contained 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-aminoisoindoline 50.0, lactose 50.7, wheat starch 7.5, PEG-6000 5.0, talc 5.0, and Mg stearate 1.8 and water qs.

AN 2001:452859 CAPLUS <<LOGINID::20080229>>
 DN 135:51096
 TI Compositions for the prevention and treatment of atherosclerosis and
 restenosis
 IN Zeldis, Jerome B.
 PA Celgene Corp., USA
 SO PCT Int. Appl., 40 pp.
 CODEN: PIXXD2


DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001043743	A1	20010621	WO 2000-US33708	20001213 <--
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	US 2002054899	A1	20020509	US 2000-734460	20001211 <--
	US 7182953	B2	20070227		
	CA 2395474	A1	20010621	CA 2000-2395474	20001213 <--
	AU 2001020916	A	20010625	AU 2001-20916	20001213 <--
	AU 782753	B2	20050825		
	EP 1242082	A1	20020925	EP 2000-984269	20001213 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	JP 2003517012	T	20030520	JP 2001-544881	20001213 <--
	US 2006040454	A1	20060105	US 2005-216950	20050830 <--
	US 7325355	B2	20080205		
PRAI	US 1999-170820P	P	19991215	<--	
	US 2000-734460	A3	20001211	<--	
	WO 2000-US33708	W	20001213	<--	

RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 16 OF 18 CAPLUS COPYRIGHT 2008 ACS on STN
 TI Substituted 2-(2,6-dioxopiperidin-3-yl)phthalimides and 1-oxoisooindolines
 and method of reducing tnfa levels

GI



AB Substituted 2-(2,6-dioxopiperidin-3-yl)phthalimides and

1-oxo-2-(2,6-dioxopiperidin-3-yl)isoindolines (I) (one of X and Y = CO and the other is CH₂ or CO; R₁, R₂, R₃, R₄ independently is halo, Cl-4-alkyl or -alkoxy or one of R₁, R₂, R₃, R₄ is (un)substituted NH₂ and the others are H; R₅ = H or Cl-8-alkyl, benzo, Cl, F; R₆ = substituted CH₂(CO)R₈CH₂NH₂ (R₈ = m- or p-phenylene of (CH₂)_n (n = 1-4))) were claimed to reduce the levels of TNF_α in a mammal. I (R₆ = H) were prepared and used in pharmaceutical compns. Thus 1-oxo-2-(2,6-dioxo-3-methylpiperidin-3-yl)-4,5,6,7-tetrafluoroisoindoline was prepared in a multistep reaction initially from methylglutamic acid which was converted via many steps to α-amino-α-methylglutarimide which was converted via many steps to the final product.

AN 1998:795004 CAPLUS <>LOGINID::20080229>>
 DN 130:38290
 TI Substituted 2-(2,6-dioxopiperidin-3-yl)phthalimides and 1-oxoisooindolines and method of reducing tnfa levels
 IN Muller, George W.; Stirling, David I.; Chen, Roger Shen-chu
 PA Celgene Corporation, USA; Muller, George W.
 SO PCT Int. Appl., 31 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 7

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9854170	A1	19981203	WO 1998-US10886	19980528 <--
W: AI, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
RW: GH, GM, KE, LS, MW, SD, SZ,UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
US 5635517	A	19970603	US 1996-690258	19960724 <--
US 5635517	B1	19990629		
US 5798368	A	19980825	US 1996-701494	19960822 <--
HU 9903929	A2	20000528	HU 1999-3929	19970724 <--
CA 2291218	A1	19981203	CA 1998-2291218	19980528 <--
AU 9877012	A	19981230	AU 1998-77012	19980528 <--
AU 741982	B2	20011213		
EP 984955	A1	20000315	EP 1998-924959	19980528 <--
EP 984955	B1	20040901		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
CN 1258293	A	20000628	CN 1998-805614	19980528 <--
TR 200000107	T2	20000721	TR 2000-107	19980528 <--
HU 2000003217	A2	20010628	HU 2000-3217	19980528 <--
HU 2000003217	A3	20020328		
NZ 501429	A	20011130	NZ 1998-501429	19980528 <--
JP 2002501536	T	20020115	JP 1999-500909	19980528 <--
RU 2209207	C2	20030727	RU 1999-128073	19980528 <--
AT 275139	T	20040915	AT 1998-924959	19980528 <--
EP 1486496	A1	20041215	EP 2004-77432	19980528 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, LT, LV, FI, MK, CY, AL				
PT 984955	T	20050131	PT 1998-924959	19980528 <--
ES 2229497	T3	20050416	ES 1998-924959	19980528 <--
TR 200500299	T2	20050621	TR 2005-299	19980528 <--
CN 1680367	A	20051012	CN 2005-10052590	19980528 <--
PL 193276	B1	20070131	PL 1998-337124	19980528 <--


CN 1911927	A	20070214	CN 2006-10126264	19980528 <--
FI 9902490	A	20000127	FI 1999-2490	19991123 <--
NO 9905751	A	20000128	NO 1999-5751	19991123 <--
NO 322080	B1	20060814		
MX 9910998	A	20000731	MX 1999-10998	19991129 <--
US 6395754	B1	20020528	US 2000-445002	20000222 <--
US 2002173658	A1	20021121	US 2002-143416	20020510 <--
US 2003144325	A1	20030731	US 2003-337602	20030106 <--
US 7119106	B2	20061010		
US 2005131024	A1	20050616	US 2005-35817	20050114 <--
US 2006160854	A1	20060720	US 2005-280333	20051117 <--
NO 2006001455	A	20000128	NO 2006-1455	20060330 <--
US 2006178402	A1	20060810	US 2006-401862	20060412 <--
US 2006183910	A1	20060817	US 2006-401858	20060412 <--
PRAI US 1996-690258	A	19960724	<--	
US 1996-701494	A	19960822	<--	
US 1997-48278P	P	19970530	<--	
CN 1998-805614	A3	19980528	<--	
EP 1998-924959	A3	19980528	<--	
WO 1998-US10886	W	19980528	<--	
US 1999-230389	A3	19990507	<--	
US 2000-445002	A1	20000222	<--	
US 2000-543809	A1	20000406	<--	
US 2001-781179	A1	20010212	<--	
US 2002-143416	A3	20020510	<--	
US 2003-337602	A3	20030106		

OS MARPAT 130:38290

RE.CNT 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 17 OF 18 CAPLUS COPYRIGHT 2008 ACS on STN
TI Substituted 2-(2,6-dioxo-3-piperidinyl)phthalimides and -1-oxoisindolines
and method of reducing TNF- α levels

GI



AB Title compds. I (X = O, H2; R = H, alkyl, benzyl, halo; R1, R2, R3, R4 = H, alkyl, alkoxy, halo, amino) were prepared for TNF- α reduction in mammals. Thus, I (X = O, R = R1 = R3 = R4 = H, R2 = NO2), prepared from 4-nitrophthalic anhydride and α -aminoglutaramide hydrochloride, was hydrogenated over 10% Pd/C in 1,4-dioxane at 50 psi for 6.5 h to give 69% I (X = O, R = R1 = R3 = R4 = H, R2 = NH2). Several examples of formulations were given.

AN 1998:87727 CAPLUS <>LOGINID::20080229>>

DN 128:140615

TI Substituted 2-(2,6-dioxo-3-piperidinyl)phthalimides and -1-oxoisindolines and method of reducing TNF- α levels

IN Muller, George W.; Stirling, David I.; Chen, Roger Shen-chu

PA Celgene Corp., USA; Muller, George W.; Stirling, David I.; Chen, Roger

Shen-Chu
 SO PCT Int. Appl., 48 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 7


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9803502	A1	19980129	WO 1997-US13375	19970724 <--
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU				
RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
US 5635517	A	19970603	US 1996-690258	19960724 <--
US 5635517	B1	19990629		
US 5798368	A	19980825	US 1996-701494	19960822 <--
AU 9738998	A	19980210	AU 1997-38998	19970724 <--
AU 715779	B2	20000210		
EP 925294	A1	19990630	EP 1997-936295	19970724 <--
EP 925294	B1	20021211		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
NZ 333903	A	20000228	NZ 1997-333903	19970724 <--
JP 20010503384	T	20010313	JP 1998-507259	19970724 <--
RU 2177944	C2	20020110	RU 1999-103124	19970724 <--
AT 229521	T	20021215	AT 1997-936295	19970724 <--
PL 191566	B1	20060630	PL 1997-332867	19970724 <--
PL 195916	B1	20071130	PL 1997-373743	19970724 <--
FI 9900101	A	19990319	FI 1999-101	19990119 <--
HK 1021819	A1	20030718	HK 1999-106117	19991224 <--
US 6281230	B1	20010828	US 2000-543809	20000406 <--
US 6476052	B1	20021105	US 2000-633908	20000807 <--
US 6316471	B1	20011113	US 2000-634061	20001017 <--
US 6335349	B1	20020101	US 2000-716528	20001120 <--
US 2002045643	A1	20020418	US 2001-781179	20010212 <--
US 6555554	B2	20030429		
US 2002183360	A1	20021205	US 2002-119486	20020410 <--
US 7041680	B2	20060509		
US 2003144325	A1	20030731	US 2003-337602	20030106 <--
US 7119106	B2	20061010		
US 2006160854	A1	20060720	US 2005-280333	20051117 <--
US 2006178402	A1	20060810	US 2006-401862	20060412 <--
US 2006183910	A1	20060817	US 2006-401858	20060412 <--
PRAI US 1996-690258	A	19960724	<--	
US 1996-701494	A	19960822	<--	
WO 1994-US7411	A	19940701	<--	
US 1997-48278P	P	19970530	<--	
US 1997-230389	B3	19970724	<--	
WO 1997-US13375	W	19970724	<--	
US 1999-230389	B3	19990507	<--	
US 2000-543809	A1	20000406	<--	
US 2000-633908	A1	20000807	<--	
US 2001-781179	A1	20010212	<--	
US 2003-337602	A3	20030106		

OS MARPAT 128:140615

RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 18 OF 18 CAPLUS COPYRIGHT 2008 ACS on STN
 TI Method of reducing TNF α levels with
 amino-substituted 2-(2,6-dioxopiperidin-3-yl)-1-oxo- and
 1,3-dioxoisindolines

GI



I

AB 1-Oxo- and 1,3-dioxo-2-(2,6-dioxopiperidin-3-yl)isoindolines (I; 1 of X, Y = C:O; other of X, Y = C:O, CH2) substituted with amino in the benzo ring are prepared which reduce the levels of TNF α in a mammal. I are therefore useful in treatment of inflammatory, infectious, immunol., or malignant diseases. Thus, 1,3-dioxo-2-(2,6-dioxopiperidin-3-yl)-5-aminoisoindoline (II) was prepared by catalytic hydrogenation of the corresponding 5-nitro compound (prepared from 4-nitrophthalic anhydride and α -aminoglutaramide-HCl) over Pd/C. Tablets each containing 50 mg II were prepared from a mixture of II 50.0, lactose 50.7, wheat starch 7.5, PEG-6000 5.0, talc 5.0, Mg stearate 1.8 g, and sufficient water for granulation.

AN 1997:375290 CAPLUS <>LOGINID::20080229>

DN 127:86110

TI Method of reducing TNF α levels with
 amino-substituted 2-(2,6-dioxopiperidin-3-yl)-1-oxo- and
 1,3-dioxoisindolines

IN Muller, George W.; Stirling, David I.; Chen, Roger S. -c

PA Celgene Corp., USA

SO U.S., 7 pp.

CODEN: USXXAM

DT Patent

LA English

FAN.CNT 7

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 5635517	A	19970603	US 1996-690258	19960724 <--
US 5635517	B1	19990629		
CA 2261762	A1	19980129	CA 1997-2261762	19970724 <--
CA 2560523	A1	19980129	CA 1997-2560523	19970724 <--
WO 9803502	A1	19980129	WO 1997-US13375	19970724 <--
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU				
RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9738998	A	19980210	AU 1997-38998	19970724 <--
AU 715779	B2	20000210		
EP 925294	A1	19990630	EP 1997-936295	19970724 <--
EP 925294	B1	20021211		

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO

CN 1239959 A 19991229 CN 1997-180299 19970724 <--

CN 1117089 B 20030806 19970724 <--

NZ 333903 A 20000228 NZ 1997-333903 19970724 <--

JP 2001503384 T 20010313 JP 1998-507259 19970724 <--

RU 2177944 C2 20020110 RU 1999-103124 19970724 <--

AT 229521 T 20021215 AT 1997-936295 19970724 <--

EP 1285916 A1 20030226 EP 2002-12942 19970724 <--

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, AL

PT 925294 T 20030430 PT 1997-936295 19970724 <--

ES 2187805 T3 20030616 ES 1997-936295 19970724 <--

CZ 295762 B6 20051012 CZ 1999-202 19970724 <--

PL 191566 B1 20060630 PL 1997-332867 19970724 <--

PL 195916 B1 20071130 PL 1997-373743 19970724 <--

WO 9854170 A1 19981203 WO 1998-US10886 19980528 <--

W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE,
DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG,
KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX,
NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT,
UA, UG, US, UZ, VN, YU, ZW

RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES,
FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI,
CM, GA, GN, ML, MR, NE, SN, TD, TG

FI 9900101 A 19990319 FI 1999-101 19990119 <--

HK 1021819 A1 20030718 HK 1999-106117 19991224 <--

US 6281230 B1 20010828 US 2000-543809 20000406 <--

US 6476052 B1 20021105 US 2000-633908 20000807 <--

US 6316471 B1 20011113 US 2000-634061 20001017 <--

US 6335349 B1 20020101 US 2000-716528 20001120 <--

US 2002045643 A1 20020418 US 2001-781179 20010212 <--

US 6555554 B2 20030429 20030106 <--

US 2003144325 A1 20030731 US 2003-337602 20030106 <--

US 7119106 B2 20061010 20060412 <--

US 2006160854 A1 20060720 US 2005-280333 20051117 <--

US 2006178402 A1 20060810 US 2006-401862 20060412 <--

US 2006183910 A1 20060817 US 2006-401858 20060412 <--

PRAI WO 1994-US7411 A 19940701 <--

US 1996-690258 A 19960724 <--

US 1996-701494 A 19960822 <--

US 1997-48278P P 19970530 <--

CA 1997-2261762 A3 19970724 <--

EP 1997-936295 A3 19970724 <--

US 1997-230389 B3 19970724 <--

WO 1997-US13375 W 19970724 <--

US 1999-230389 B3 19990507 <--

US 2000-543809 A1 20000406 <--

US 2001-781179 A1 20010212 <--

US 2003-337602 A3 20030106 <--

OS MARPAT 127:86110